| GIMERACIL | Small molecule | head and neck malignant neoplasia | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic ductal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | breast neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | biliary tract cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | nasopharyngeal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | metastatic colorectal cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Suspended | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastroesophageal junction adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | Digestive System Carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | non-small cell lung carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Suspended | ClinicalTrials |
| GIMERACIL | Small molecule | cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Terminated | ClinicalTrials |
| GIMERACIL | Small molecule | nasopharyngeal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | cervical cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | hepatocellular carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Suspended | ClinicalTrials |
| GIMERACIL | Small molecule | breast cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Terminated | ClinicalTrials |
| GIMERACIL | Small molecule | non-small cell lung carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | biliary tract cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Terminated | ClinicalTrials |
| ENILURACIL | Small molecule | cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Terminated | ClinicalTrials |
| GIMERACIL | Small molecule | biliary tract cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | head and neck malignant neoplasia | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| GIMERACIL | Small molecule | rectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| ENILURACIL | Small molecule | colorectal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | secondary malignant neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | breast neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| ENILURACIL | Small molecule | rectum cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | nasopharyngeal neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Terminated | ClinicalTrials |
| GIMERACIL | Small molecule | gastroesophageal junction adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | rectum cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | hepatocellular carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| GIMERACIL | Small molecule | rectum cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | non-small cell lung carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | neuroendocrine carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | metastatic colorectal cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | hepatocellular carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | biliary tract cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | head and neck malignant neoplasia | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| ENILURACIL | Small molecule | malignant colon neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| ENILURACIL | Small molecule | head and neck malignant neoplasia | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Terminated | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | metastatic colorectal cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| ENILURACIL | Small molecule | lymphoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | head and neck squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| ENILURACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | non-small cell lung carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| ENILURACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | cholangiocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | biliary tract cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic ductal adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | small cell lung carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | colorectal carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| ENILURACIL | Small molecule | breast cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal cancer | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal cancer | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | head and neck squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | gastric adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | pancreatic carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 1.0 | Suspended | ClinicalTrials |
| GIMERACIL | Small molecule | esophageal squamous cell carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric adenocarcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| GIMERACIL | Small molecule | gastric carcinoma | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| GIMERACIL | Small molecule | gastric cancer | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |
| GIMERACIL | Small molecule | stomach neoplasm | Dihydropyrimidine dehydrogenase inhibitor | 3.0 | Completed | ClinicalTrials |